AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

3D rendering of a blue virus particle surrounded by yellow antibodies, illustrating an immune response at the microscopic level Featured image for article: AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

The Delhi High Court has dismissed AbbVie’s appeal regarding the refusal of their patent application for an anti-cMet antibody-drug conjugate. The court found the proposed amendments exceeded permissible scope under the Indian Patents Act.

Read more about AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

Claim Amendments within the Scope of Patent Specification are Permissible, the Delhi High Court reiterates

The Delhi High Court has reaffirmed that claim amendments falling within the scope of the original patent specification are permissible under Indian law. The judgment provides clarity on Section 59(1) of the Patents Act and sets important precedent for future patent amendment cases.

Read more about Claim Amendments within the Scope of Patent Specification are Permissible, the Delhi High Court reiterates